A few big approvals stole the spotlight at the US FDA last week, including Sun Pharmaceutical Industries Ltd.'spsoriasis treatment Ilumya (tildrakizumab-asmn), which became the second biologic approved by the Center for Drug Evaluation and Research (CDER) and the sixth overall CDER-approved novel agent in 2018. It was also the first standard review novel approval of 2018.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?